Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, Frankfurt: HBP0), a clinical-stage oncology company focused on developing therapies for difficult-to-treat cancers, has announced immediate changes to its Board of Directors. Janusz Grabski has resigned from the board, effective immediately. Concurrently, the board has formally appointed Thomas Mehrling, M.D., Ph.D., the company's Chief Executive Officer, as a director. This appointment is made pursuant to the board nomination right granted to Laevoroc Immunology AG in connection with Helix's 2025 acquisition of substantially all of the assets of Laevoroc Immunology AG and Laevoroc Chemotherapy AG.
These changes are intended to ensure that the board continues to meet Helix's evolving governance and capital markets requirements. The board believes that the new composition, with Dr. Mehrling's extensive experience in oncology drug development and corporate leadership, will better support the company's clinical development and broader corporate objectives. The board expressed gratitude to Mr. Grabski for his service and contributions, wishing him success in his future endeavors.
The strategic significance of these board changes lies in the alignment of leadership with the company's pipeline advancement. Helix's lead candidate, L-DOS47, is an antibody-enzyme conjugate in clinical development for non-small cell lung cancer (NSCLC). The company also has pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a gemcitabine prodrug for advanced solid tumors. These assets were acquired from the Laevoroc group in a strategic acquisition, as detailed in the company's acquisition announcement. Dr. Mehrling's appointment ensures that the board has direct insight into the company's scientific and strategic direction, which is crucial for guiding these assets through clinical development and towards potential commercialization.
For investors, this board restructuring signals a commitment to strong governance and strategic focus. By placing the CEO on the board, Helix aims to streamline decision-making and enhance accountability, which is often viewed favorably by the market. The resignation of Mr. Grabski may also indicate a shift in board composition to better match the company's current phase of growth. As Helix continues to progress its pipeline, such governance adjustments are critical to maintaining investor confidence and securing the necessary capital to fund future trials.
Helix BioPharma is a clinical-stage oncology company dedicated to developing therapies for underserved patient populations with difficult-to-treat cancers. The company's common shares are listed on the Toronto Stock Exchange (TSX: HBP), quoted on the OTC Pink Market (HBPCD), and listed on the Frankfurt Stock Exchange (FWB: HBP0). For more information, visit Helix BioPharma's website.
